Pharma society 5.0 "Moonshot" - Our Strategic Path Forward

2021 Annual Meeting Program (Japan Affiliate)

As of 2021/5/13

May 13 Annual General Meeting 9:30-10:15

| | 9:30-10:15 | | 9:30-10:30 Annual General Meeting | MC: Akihiro Matsuki | Head of Secretariat | |
|----|------------|----|---|---------------------|---------------------------------|--|
| | | | Welcome | Ayako Nakajima | Chairman | |
| | | | Nomination and Election of AGM chairman | | | |
| | | | 2020 Activity Report | Akihiro Matsuki | Head of Secretariat | |
| AM | | 45 | 2020 Financial Report | Hiroshi Yamaguchi | Treasurer | |
| | | | 2020 Internal Audit Report | Shigeru Nakamura | Japan Affiliate Auditor | |
| | | | 2021 Action Plan | Akihiro Matsuki | Head of Secretariat | |
| | | | 2021 Budget Proposal | Hiroshi Yamaguchi | Treasurer | |
| | | | 2021 Election Results of Board & Officers | Tetsuro Noguchi | 2020 Head of Election Committee | |

May 13 Annual Conference 10:15-17:15

| Venue | Time | minutes | | Title | Speaker | Affiliation | Moderator | Affiliation |
|---------------|-------------|---------|---------------------------|---|---------------------------------|--|------------------|--|
| | 10:15-10:20 | | Orientation | | MC:Akihiro Matsuki | Head of Secretariat, Mitsubishi Chemical Engineering Corporation. | | |
| | 10:20-10:25 | 5 | Opening Remarks 1 | Welcome and Opening | ISPE Japan Affiliate 2021 Chair | | | |
| 2F Event Hall | 10:25-11:10 | 45 | Keynote Speech 1 | Future Generational Concerns in the Medical and Pharma World - Growth in a Turbulent Era | Norikazu Eiki | Former Chair of Bayer Yakuhin Ltd. | Hirofumi Suzuki | ISPE International Board, Bayer Yakuhin, Ltd. |
| | 11:10-11:55 | 45 | Keynote Speech 3 | Tumor Re-Engineering: Developing Novel Immuno-Gene Therapies for Cancer (Recorded) | Brian R. Champion, Ph.D. | Chief Scientific Officer at PsiOxus Therapeutics | | |
| 2F Event Hall | 11:55-12:50 | 55 | Lunch (Luncheon Seminar) | | | | | |
| 2F Event Hall | 12:50-13:15 | 25 | Keynote Speech 4 | 2020 Annual Meeting Keynote GSK - Manufacturing Autologous Ex Vivo Genetically Modified Cell Therapies Have Challenges but the Future is Bright | S. Joseph Tarnowski, Ph.D. | Senior Vice President, Cell & Gene Therapy Platform, GSK | | |
| | 13:15-13:45 | 30 | | KASA: Opportunity for Modernizing Regulatory Assessment and Submission | Lawrence Yu, Ph.D. | Director, Office of New Drug Products, CDER, FDA | | |
| 2F Event Hall | 13:45-14:00 | 15 | Break | | | | | |
| 2F Event Hall | 14:00-14:45 | 45 | Keynote Speech 2 | MHLW Update (Tentative) | Fumi Yamamoto | Councilor for Pharmaceutical Affairs Minister. S Secretariat MHLW | Ayako Nakajima | ISPE Japan Affiliate Chair, Q&EHS Solutions, Co., Ltd. |
| 21 Evolution | 14:45-15:05 | 20 | Update from ISPE Global | ISPE for the 21st Century and Beyond | Joanne R. Barrick, RPh | ISPE Global Chair | | |
| 2F Event Hall | 15:05-15:40 | 35 | Lunch (Luncheon Seminar) | | | | | |
| | 15:40-16:25 | 45 | Special Lecture 1 | The Challenge of Digital Transformation of Chugai Pharmaceutical | Yoshito Nakanishi | Chugai Pharma Manufacturing Co., Ltd. | Daisuke Hirasawa | ISPE Japan Affiliate Board of Directors Chugai Pharma Manufacturing Co., Ltd. |
| 2F Event Hall | 16:25-17:10 | 45 | Special Lecture 2 | Development of Data-Driven Chemistry | Kimito Funatsu | Professor, Tokyo University | Tetsuro Noguchi | ISPE Japan Affiliate Board of Directors Nobelpharma Co., Ltd. |
| | 17:10-17:15 | 5 | Closing Remarks for Day 1 | | Tetsuro Noguchi | Chairman, 2021 Annual Meeting Organizing Committee/ Japan Affiliate Board of Director | | |

May 14 Workshops 9:30-17:00

| Venue | Time | minutes | | Title | Speaker | Affiliation | Moderator | Affiliation |
|-----------|--------------------|------------|---|--|--------------------|---|-----------|-------------|
| 2 F Zuiun | 9:30-12:45 Works | hop 1 Fol | F (Facilities of the Future) | | | | | |
| | Theme: Facility of | f the Futu | re/ Implementation of Soft sens | sor for Quality Control in Continuous Manufacturing | | | | |
| | 9:30-9:35 | 5 | Openning Remarks | | Tetsuro Noguchi | Japan Affiliate Board of Director / Nobelpharma Co.,Ltd. | | |
| | 9:35-9:50 | 15 | Continuous manufacturing - Qua | ality control for Granulation Process - | Takashi Terada | FREUND CORPORATION | | |
| | 9:50-10:05 | 15 | Continuous manufacturing - Qua | ality control for Tableting Process - | Shinsuke Fushimi | KIKUSUI SEISAKUSHO LTD. | | |
| | 10:05-10:20 | 15 | Continuous manufacturing - Qua | ality control for Coating Process - | Kazuhiro Uchida | POWREX CORPORATION | | |
| | 10:20-10:35 | 15 | Points of attention for Continuou | us Manufacturing using NIRS (Near-infrared spectroscopy) | Munetaka Hattori | PAT COP Leader/Pharmaceutical Consultant | | |
| АМ | 10:35-10:50 | 15 | Break | | | | | |
| , | 10:50-11:30 | 40 | Toward implementation of soft s | sensor for continuous production process | Kimito Funatsu | Professor, Tokyo University | | |
| | 11:30-11:40 | 10 | Break | | | | | |
| | 11:40-12:15 | 35 | PMDA's Activities for Continuous | us Manufacturing | Yoshihiro Matsuda | Specialist(Quality), Pharmaceuticals and Medical Devises Agency (| PMDA) | |
| | 12:15-12:25 | 10 | Break | | | | | |
| | 12:25-12:45 | 20 | FOF Q & A session | | All speaker | | | |
| | 12:45-13:45 | 60 | Lunch | | | | | |
| 2 F Zuiun | 13:45-17:00 Wor | kshop 6 (| C&Q COP | | | | | |
| | テーマ:The first | revision i | n 18 years, the outline of ISPE | Baseline Guide Volume 5 Commissioning and Qualification Second | d Edition | | | |
| | 13:45-13:50 | 5 | Orientation | | Hinako Aoki | C&Q COP | N/A | |
| | 13:50-14:15 | 25 | 1. Introduction | | Daisuke Hamaguchi | C&Q COP | N/A | |
| | 14:15-14:40 | 25 | User Requirements Specifica System Classification | ation | Mayo Mimura | C&Q COP | N/A | |
| | 14:40-15:05 | 25 | 4. System Risk Assessment 5. Design Review and Design Q | Qualification | Daisuke Hamaguchi | C&Q COP | N/A | |
| PM | 15:05-15:30 | 25 | 6. C&Q Planning 7. C&Q Testing and Documenta | ation | Masahiko Yamaguchi | C&Q COP | N/A | |
| | 15:30-15:45 | 15 | Break | | | | | |
| | 15:45-16:10 | 25 | 8. Acceptance and Release 9. Periodic Review | | Mototsugu Mine | C&Q COP | N/A | |
| | 16:10-16:35 | 25 | 10. Vendor Assessment for C&C 11. Engineering Quality Process | | Noboru Osaka | C&Q COP | N/A | |
| | 16:35-17:00 | 25 | 12. Change Management 13. Good Documentation Practi 14. Strategies for Implementati | tice for C&Q ion of Science and Risk-Based C&Q Process | Masataka Tsuda | C&Q COP | N/A | |

| Venue | Time | minutes | | Title | Speaker | Affiliation | Moderator | Affiliation |
|------------|---|-----------|--|---|--------------------------------------|---|------------------|----------------------------------|
| 2 F Heian | 9:30-12:45 Worksh | nop 2 SP | РСОР | | MC: Koji Kawasaki | SPP COP Leader, Airex Co.,Ltd. | | |
| | Theme: Shhh Sl | ashing Th | e Microbial Kingdom | | | | | |
| | 9:30-9:40 | 10 | Introduction of SPP COP | | Koji Kawasaki | SPP COP Leader, Airex Co.,Ltd. | | |
| | 9:40-10:20 | 40 | Study of Material Transfer to | | Kén wagai Sèlifi Shltfiura | Airex Co., Ltd. Tarray Fagiltagring Co. Ltd | Kentaro Nakamura | JGC JAPAN CORPORATION |
| | 10:20-11:20 | 60 | The same way as Multi-use | system? \sim Inherent risks and consideration timings for Single-use | Norioki Masai | Ninon Pall Ltd. Nadase Medicals Co. Ltd. | Seiji Shimura | Nihon Pall Ltd. |
| AM | 11:20-11:35 | 15 | Break | | | | | |
| | 11:35-12:35 | 60 | Time dependency of HEPA | Filter performance during load test with high concentration | Kodai Chiba | TEC Project Services Corporation | Katsuya Inoue | ASAHI KOGYOSHA CO.,LTD. |
| | 12:35-12:45 | 10 | Progress report on the publi Third Edition" Japanese trai | ication of "Baseline Guide Vol.3: Sterile Product Manufacturing Facilities nslation | Shigeru Okumura | TEC Project Services Corporation | Shigeru Okumura | TEC Project Services Corporation |
| | 12:45-13:45 | 60 | Lunch | | | | | |
| 2 F Heian | 13:45-17:00 Works | shop 7 Co | ntainment COP | | MC:Yuji Yamaura/Shinichiro Matsunaga | Asahi Kasei Finechem Co., Ltd./Takeda Pharmaceutical Co., Ltd. | | |
| | Theme: Risk Base | d Approa | ch for manufacturing of hig | ghly potent products | | | | |
| | 13:45-14:45 | 60 | Special Lecture Current T | hinking on Control of Cross-Contamination in Shared Facilities | Ryusei Ishii | Pharmaceuticals and Medical Devices Agency(PMDA) | | |
| | 14:45-15:00 | 15 | Containment COP Introdu | ction of Containment COP Activities | Yuji Yamaura | Asahi Kasei Finechem Co., Ltd. | | |
| РМ | 15:00-15:35 | 35 | Containment COP Aiming measurement. | to spread PEEM-DB! Correlation visualizing by analysis of exposure | Yutaro Ishikawa/Takuya Nagato | NARA Machinery Co., Ltd./Powrex Corporation | | |
| | 15:35-15:50 | 15 | Break | | | | | |
| | 15:50-16:00 | 10 | PDE setting roundtable Pr | ogress of PDE setting roundtable in Japan | Shinichiro Matsunaga | Takeda Pharmaceutical Co., Ltd. | | |
| | 16:00-16:35 | 35 | PDE Setting Roundtable A | Activities of Low-Molecular Weight Substances Subcommittee | Ichiro Tsunenari | Safety Evaluation Forum | | |
| | 16:35-17:00 | 25 | PDE Setting Roundtable A | Activities of High-Molecular Weight Substances Subcommittee | Nobuaki Kato | Chugai Pharmaceutical Co., Ltd. | | |
| 2 F Fukuju | 9:30-12:45 Works | hop 3 SA | M&GMP COP | | MC:Mamoru Kusumoto | Shin Nippon Yakugyo Co., Ltd | | |
| | テーマ: Close in u | pon the E | ssence of GMP! ~ in ligh | nt of the Revised J-GMP Ministerial Ordinance ~ | | | | |
| | 9:30-9:35 | 5 | Opening | | Satoru Arai | Toray Industries, Inc. | | |
| | 9:35-10:25 | 50 | Points for Revision of GMP | P Ministerial Ordinance and Future Prospects | Koki Akazawa | Pharmaceuticals and Medical Devices Agency Office of Manufacturing Quality for Drugs | Fumio Kishimoto | Katsura Chemical Co., Ltd |
| | 10:25-11:10 | 45 | Pharmaceutical quality ma | nagement system and Fostering quality culture | Toshio Kawakita | Shionogi Pharma Co., Ltd. | Junya Soma | GlaxoSmithKline K.K. |
| AM | 11:10-11:20 | 10 | Break | | | | | |
| | 11:20-12:00 | 40 | Cleaning Validation case st | tudy from a perspective of revised J-GMP ministerial ordinance | Yusuke Enya, Mieko Suganuma | Shin Nippon Yakugyo Co., Ltd, Sanofi K.K. | | |
| | 12:00-12:45 | 45 | Panel Discussion | | | Pharmaceuticals and Medical Devices Agency, Shionogi Pharma Co., Ltd., Q&EHS Solutions Corporation | Tsutomu Kojima | SymBio Pharmaceuticals Limited |
| | 12:45-13:45 | 60 | Lunch | | | | | |
| 2 F Fukuju | 13:45-17:00 Works | shop 8 Al | PICOP | | | | | |
| | テーマ: Continuous Manufacturing for API: Future outlook of Impemetation | | | | | | | |
| | 13:45- 13:50 | 40 | Openning Remarks | | Masatoshi.Ikeya | TEC Project Survice | | |
| | 13:50- 14:30 | 40 | Some application at Contin | nuous Manufacturing Process | Kouji.Muteki | Pfizer Pharma | Tsutomu.Kojima | SymBio Pharmaceuticals Limited |
| DNA | 14:30-15:10 | 40 | Examples of API intermedia | ate manufacturing at TAKASAGO | Michio.Kida | Takasago | Tatsuya.Watanabe | Takasago Chemical |
| PM | 15:10-15:20 | 10 | Break | | | | | |
| | 15:20-15:50 | 30 | What we can see from the | API COP discussion(Continuous Manufacturing API) | Ryouta.Sugiyama | Chugai Pharmaceutical | | |
| | 15:50-16:30 | 40 | Continuous API, what shou | | | MB Chemistry Consulting LTD | Yoshio.Hitaka | Takeda Pharmaceutical |
| | 16:30-17:15 | | PD | | | PMDA | | |
| | | | | | | | | |

| Venue | Time | minutes | | Title | Speaker | Affiliation | Moderato |
|----------|------------------------|-------------|---------------------------------|--|---------------------------|---|----------------|
| 2F Togen | 9:30-12:45 Works | shop 4 BIO | COP | • | Speaker | Affiliation | Moderator |
| AM | Strategy for bion | nanufactu | ring facility in the age of liv | ving with COVID-19 | MC: Takashi Kaminagayoshi | BIO COP Leader, Takeda | - |
| | 9:30-9:40 | 10 | Orientation | Activities Introduction | Takashi Kaminagayoshi | BIO COP Leader, Takeda | - |
| | 9:40-10:35 | 55 | Workshop 1 | Business Continuity Plan in Response to Emerging Infectious Diseases | | | Yuu Kamine |
| | | | | Environmental Analysis | Koji Iritani | Kaneka | |
| | | | | Business Continuity Plan | Masashi Oda | Hitachi Plant Services | |
| | 10:35-10:45 | 10 | | Break | | | |
| | 10:45-11:40 | 55 | Workshop 2-1 | Facility Planning against Emerging Infectious Diseases | | | Takashi Ichii |
| | | | | Preconditions | Iyo Terashima | Merck | |
| | | | | Equipment Configuration | Yuji Aoki | Nihon Pall | |
| | 11:40-11:50 | 10 | | Break | | | |
| | 11:50-12:45 | 55 | Workshop 2-2 | Facility Planning against Emerging Infectious Diseases | | | Takashi Kamina |
| | | | | Layout Plan | Takato Mizunuma | IHI Plant Services | |
| | | | | Digital Tools | Hiroaki Takamura | Chiyoda | |
| | 12:45-13:45 | 60 | Lunch | | | | |
| 2F Horai | 9:30-12:45 Works | shop 5 IP (| COP | | | | |
| | The first year of Clir | ical Supply | 5G | | | | |
| | 09:30-09:35 | 5 | | IP-COP Introduction | Mr.Yoshihiko Sato | IP-COP Chair, Mitsubishi Logistics Corporation | |
| | 09:35-10:35 | 60 | Lecture1 | Current Regulatory situation and challenges for Clinical Supply activities | Mr.Yoshihiro Sawada | IP-COP Regulatory Lead, Astra Zeneca K.K. | Shinya Otsuji |
| AM | 10:35-11:35 | 60 | Lecture2 | Dtp/DfP Tips for the local further growth | Mr.Minoru Mihara | IP-COP DtP/DfP WG Lead, Marken Japan Limited. | Naoya Okamura |
| | 11:35-11:40 | 5 | Break | | | | |
| | 11:40-12:40 | 60 | Lecture3 | Roles and Challenges of Clinical Supply in Airport | Mr.Kenichi Kuchiki | IP-COP Outsouring Lead, Mitsui-Soko Holdings Co.,Ltd. | Yoshihiko Sato |
| | 12:40-12:45 | 5 | | IP-COP Closing | Mr.Yoshihiko Sato | IP-COP Chair, Mitsubishi Logistics Corporation | |

| ator | Affiliation |
|-----------|---|
| | Affiliation |
| | - |
| | - |
| | Kirin Engineering |
| | |
| | Nihon Pall |
| | |
| nagayoshi | BIO COP Leader, Takeda |
| | |
| | |
| | |
| | |
| | IP-COP Regulatory WG, Saroute Co.,Ltd. |
| | IP-COP DtP/DfP、Mitsubishi Logistics Corporation |
| | |
| | IP-COP Chair, Mitsubishi Logistics Corporation |
| | |